NEW YORK, NY / ACCESSWIRE / February 21, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
DOCU Shareholders Click Here: https://www.zlk.com/pslra-1/docusign-inc-loss-submission-form?prid=23885&wire=1
CLVT Shareholders Click Here: https://www.zlk.com/pslra-1/clarivate-plc-loss-submission-form?prid=23885&wire=1
BIIB Shareholders Click Here: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form-2?prid=23885&wire=1
* ADDITIONAL INFORMATION BELOW *
Docusign, Inc. (NASDAQ:DOCU)
DOCU Lawsuit on behalf of: investors who purchased March 27, 2020 - December 2, 2021
Lead Plaintiff Deadline: February 22, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/docusign-inc-loss-submission-form?prid=23885&wire=1
According to the filed complaint, during the class period, Docusign, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the impact of the Covid-19 pandemic on DocuSign's business was positive, not negative; (2) DocuSign misrepresented the role that the Covid-19 pandemic had on its growth; (3) DocuSign downplayed the impact that a ‘return to normal' would have on the Company's growth and business; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Clarivate Plc (NYSE:CLVT)
CLVT Lawsuit on behalf of: investors who purchased February 26, 2021 - December 27, 2021
Lead Plaintiff Deadline: March 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/clarivate-plc-loss-submission-form?prid=23885&wire=1
According to the filed complaint, during the class period, Clarivate Plc made materially false and/or misleading statements and/or failed to disclose that: (i) Clarivate maintained defective disclosure controls and procedures as a result of a material weakness in its internal control over financial reporting; (ii) the foregoing material weakness was not limited to how the Company accounted for warrants; (iii) as a result, Clarivate failed to properly account for an equity plan included in its acquisition of CPA Global, a global leader in Intellectual Property software and tech-enabled services; (iv) accordingly, the Company was reasonably likely to restate one or more of its previously issued financial statements following its acquisition of CPA Global; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Biogen Inc. (NASDAQ:BIIB)
BIIB Lawsuit on behalf of: investors who purchased June 7, 2021 - January 11, 2022
Lead Plaintiff Deadline: April 8, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form-2?prid=23885&wire=1
According to the filed complaint, during the class period, Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) there was a significant, undisclosed lobbying campaign between Biogen and the Food and Drug Administration ("FDA") that was instrumental in the decision to file and approve Aduhelm, a drug being developed to treat Alzheimer's disease; 2) the Phase III ENGAGE study demonstrated that Aduhelm failed to achieve a clinical benefit to Alzheimer's patients; 3) ENGAGE was a failed study from which Biogen concluded not to seek FDA approval for Aduhelm in 2019; and 4) defendants misled investors as to the way in which approval was achieved, that the clinical data did not support a clinical benefit by taking Aduhelm and that side-effects were dangerous and serious
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE : Levi & Korsinsky, LLP